Compare Novavax Inc (NVAX) vs iShares Silver Trust (SLV) Price & Performance

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

SLV trades at $59.24, down 0.29% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, though prices eased ahead of CPI data. Financial ratios are unavailable as SLV is an ETF tracking physical silver, not a company with earnings.

The outlook for SLV hinges on silver's industrial and monetary demand, with support from AI infrastructure needs and potential Fed dovishness. Risks include dollar strength, inflation data surprises, and volatility from leveraged ETF comparisons. Investors gain pure silver exposure without mining operational risks.